SCHEMBL709802

SCHEMBL709802

[Li]Cc1cccnc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL317315 0.80
SCHEMBL727185 0.79 CYP1A2 (0.62)
SCHEMBL724866 0.79 CHRNA7 (0.74)
SCHEMBL29485692 0.79 CHRNA7 (0.74)
SCHEMBL45429 0.75
SCHEMBL177990 0.75
SCHEMBL8219678 0.75
SCHEMBL4012197 0.75 CYP1A2 (0.58)
SCHEMBL3936550 0.75 CYP1A2 (0.58)
SCHEMBL770032 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541447-B2 3-substituted-2-(arlyalkyl)-1-azabicycloalkanes and methods of use thereof TARGACEPT, INC. (US) 2013-09-24 US disclosed
EP-2018364-B1 THERAPEUTIC FLUOROETHYL UREAS ALLERGAN INC (US) 2013-08-21 EP disclosed
US-20120136024-A1 3-Substituted-2-(arlyalkyl)-1-azabicycloalkanes and Methods of Use Thereof TARGACEPT, INC. (US) 2012-05-31 US disclosed
US-8158649-B2 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof TARGACEPT, INC. (US) 2012-04-17 US disclosed
US-8143272-B2 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof TARGACEPT, INC. (US) 2012-03-27 US disclosed
US-8124618-B2 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof TARGACEPT, INC. (US) 2012-02-28 US disclosed
US-8124619-B2 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof TARGACEPT, INC. (US) 2012-02-28 US disclosed
US-8124620-B2 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof TARGACEPT, INC. (US) 2012-02-28 US disclosed
US-8084462-B2 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof TARGACEPT, INC. (US) 2011-12-27 US disclosed
US-20110071187-A1 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF TARGACEPT, INC. (US) 2011-03-24 US disclosed
EP-1594869-A2 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF Targacept, Inc. (US) 2005-11-16 EP disclosed
US-6953855-B2 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof TARGACEPT, INC. (US) 2005-10-11 US disclosed
WO-2004076449-A2 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF TARGACEPT, INC. (US) 2004-09-10 WO disclosed
US-20040152723-A1 Pharmaceutical compositions and methods for use CLARK THOMAS JEFFREY (US) 2004-08-05 US disclosed
US-20040002513-A1 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof ATTENUA, INC. 2004-01-01 US disclosed
US-6624167-B1 Compounds that are capable of affecting nicotinic cholinergic receptors. A wide variety of conditions and disorders, and particularly conditions and disorders associated with dysfunction of the central and autonomic nervous systems can TARGACEPT, INC. 2003-09-23 US disclosed
EP-1305316-A2 AZABICYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE Targacept, Inc. (US) 2003-05-02 EP disclosed
WO-2002012245-A2 AZABICYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE TARGACEPT, INC. (US) 2002-02-14 WO disclosed
EP-0594629-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL USE BRITISH TECHNOLOGY GROUP LTD (GB) 1994-05-04 EP disclosed
WO-1992016507-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL USE BRITISH TECHNOLOGY GROUP LIMITED (GB) 1992-10-01 WO disclosed